Femen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Femen

Property Description
Active ingredient Ibuprofen
Form Tablets or Capsules
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic (Propionic acid derivative)

Femen is a pharmaceutical product defined by its sole active ingredient, Ibuprofen, and its classification as a widely used Non-Steroidal Anti-Inflammatory Drug (NSAID). This medicine is designed for oral administration to provide systemic relief from symptoms associated with pain, inflammation, and fever throughout the body.

What Type of Medicine is Femen?

Femen is a synthetic compound belonging to the propionic acid derivative class of drugs. This classification means the medicine is chemically synthesized and functions by interfering with specific physiological pathways. Ibuprofen, the active substance, is used to reduce the severity of pain. This confirms the medicine's role in easing physical discomfort. Femen is often commercially positioned toward relief of menstrual discomfort, distinguishing its specific market focus from generalized pain relievers. Femen's composition is a single active ingredient product, ensuring that its effects are derived exclusively from the pharmacological properties of Ibuprofen. The preparation's identity is rooted in its definitive triple action as an anti-inflammatory, analgesic (pain-reliever), and antipyretic (fever-reducer).

Composition and General Therapeutic Purpose

Femen is typically formulated into solid forms, such as film-coated tablets or capsules, which are taken by mouth. These forms require standard pharmaceutical excipients to ensure stability and proper systemic absorption, differentiating them from liquid or topical preparations. Its general therapeutic purpose is to offer symptomatic relief by targeting the biological process that generates inflammation and pain. This drug class is recognized for its role in reducing signs of inflammation. This indicates that the medicine directly addresses the root causes of swelling and irritation. The active ingredient's action is clinically recognized for its rapid onset compared to some other NSAIDs, which is a feature often highlighted for acute symptomatic relief. The active ingredient works to reduce swelling and irritation, diminish pain signaling, and help reset the body's internal thermostat to a normal temperature. This systemic action ensures that the relief is distributed wherever pain and inflammation are manifesting, providing comprehensive, high-level symptomatic relief.

Regulatory References

  1. National Institutes of Health (NIH) emphasizes the consistent efficacy of this drug class in reducing signs of inflammation

What side effects are possible with Femen?

Possible side effects and safety information

The safety profile of Femen (Ibuprofen) is formally classified by regulatory authorities, with adverse reactions grouped by both frequency and the physiological system affected. The most frequently documented effects relate to the Gastrointestinal Disorders system.

Commonly documented adverse reactions include general gastrointestinal disturbances such as dyspepsia, nausea, abdominal pain, vomiting, and flatulence, as defined by frequency bands in official prescribing information.


Serious Adverse Reactions and Safety Constraints

The official labeling includes mandatory warnings for serious but less common risks. These are often categorized as Rare in frequency but are clinically significant:

  • Serious Cardiovascular Thrombotic Events: Regulatory documents warn of the potential risk of myocardial infarction (heart attack) and stroke, which may occur early in treatment, and this risk is documented as more likely with higher doses and longer duration of use.
  • Serious Gastrointestinal Events: The risk of severe events, including gastrointestinal bleeding, ulceration, and perforation, is a key concern highlighted in regulatory documentation, particularly with chronic exposure.

Population-Specific Safety Notes

The safety profile mandates constraints for specific patient populations. Older adults are documented to have a greater risk of serious adverse reactions, particularly fatal gastrointestinal and cardiovascular events. The medicine is contraindicated in patients with active gastrointestinal haemorrhage or ulceration, as well as in those with severe, uncontrolled cardiac, hepatic, or renal failure. These constraints formally define the high-level safety limitations documented in the drug's regulatory profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the manifestations and required emergency response following an overdose of Femen (Ibuprofen).

Immediate Action Mandate: Seek immediate medical attention or contact the local emergency number or a poison control center (such as 1-800-222-1222 in the US) immediately after any suspected ingestion of more than the maximum recommended dose, even if the individual remains without symptoms. This required action precedes and is necessary for all subsequent care.

Documented Overdose Manifestations

Symptoms are variable but often involve the Central Nervous System (CNS) and Gastrointestinal (GI) systems. The most common manifestations listed in regulatory labeling include Nausea, Vomiting, Abdominal pain, Headache, Dizziness, and Lethargy. Severe CNS effects, such as Convulsions or Coma, are documented in cases of high exposure.

Serious Outcomes and Management

Overdose carries the risk of severe, life-threatening organ toxicities, including Acute Kidney Failure, Metabolic Acidosis, and Gastrointestinal Hemorrhage or Perforation. Individuals with pre-existing conditions like renal impairment or a history of ulcers are noted to be at a higher risk for severe outcomes. According to official labeling, no specific antidote is known or available for Ibuprofen overdose. Management is therefore strictly symptomatic and supportive, which may involve the administration of Activated Charcoal in hospital settings to reduce absorption.

Therapeutic Uses of Femen

Femen (Ibuprofen) is relevant in contexts involving heightened systemic burden and physical discomfort across various acute and episodic conditions. Its active component is considered relevant for easing symptoms related to minor aches and pains, fever, and common inflammatory conditions. This therapeutic domain encompasses supportive symptom management. Femen supports the patient during difficult episodes by easing distress and is applied in clinical settings that involve acute or unstable symptom patterns where supportive symptom management is appropriate.


The medication is applied in addressing symptom clusters that may become intense or disruptive, relevant for easing discomfort caused by headaches, dental pain, muscular aches, and primary dysmenorrhea. It is used in areas where short-term symptom management is appropriate, providing supportive relief when symptoms that interfere with daily functioning become more noticeable. This supports general well-being during symptomatic phases when symptoms create noticeable physiological strain.

“It contributes to improved comfort during periods of heightened symptoms when symptoms related to inflammatory or irritative states are present.”

Femen is relevant for easing symptoms related to systemic imbalance, such as fever and body aches associated with the common cold or flu, and is also applied in addressing recurrent or episodic manifestations like minor musculoskeletal sprains and strains.

Quick Fact: Relief for Fever

Femen provides supportive relief when symptoms become temporarily overwhelming, may help patients cope more steadily with symptom fluctuations during symptomatic phases.

Eligibility and Restrictions for Use

Official Regulatory Eligibility and Restrictions

Femen (Ibuprofen) is subject to specific population eligibility rules defined by governmental regulatory documents. These rules classify populations as either permitted, restricted, or strictly contraindicated.

Absolute Contraindications

The medicine is strictly contraindicated for patients with known hypersensitivity to Ibuprofen, aspirin, or other NSAIDs, including those with a history of NSAID-induced asthma. Absolute exclusion applies to individuals with active or recurrent gastrointestinal bleeding or peptic ulceration. It is also forbidden for patients with severe renal failure, severe hepatic failure, or severe heart failure (NYHA Class IV), as well as during the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery.

Age and Conditional Use

The safety and effectiveness of oral Femen are not established for infants under 6 months of age. While adults and adolescents are eligible, older adults and patients with mild-to-moderate renal or hepatic impairment must use with caution due to increased susceptibility to adverse effects. Conditional use also applies to patients with comorbidities such as Systemic Lupus Erythematosus (SLE) or uncontrolled hypertension.

Pregnancy Status

Femen is formally contraindicated for women in the third trimester of pregnancy. Regulatory documents recommend avoiding use after 20 weeks gestation. Use while breastfeeding is generally considered permitted at standard therapeutic doses.

What should I know about interactions with other medicines?

The official profile for Femen (Ibuprofen), an NSAID, establishes several important interaction constraints detailed in government regulatory documents. This section summarizes those formal, label-based interaction patterns and restrictions.

Interaction Type Officially Documented Outcomes and Constraints
Contraindications Co-administration is prohibited with other NSAIDs (including COX-2 inhibitors) and high-dose Aspirin (doses greater than 75 mg daily). Use is also contraindicated for treating perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Exposure Modification Femen reduces the renal clearance of Lithium and Methotrexate, which can lead to increased plasma exposure of these medicines. This effect is related to the drug's influence on renal function.
Pharmacodynamic Risk Combining Femen with Anticoagulants, Oral Corticosteroids, or SSRIs amplifies the risk of serious gastrointestinal bleeding and ulceration. Femen may also diminish the therapeutic effects of certain Anti-hypertensives and Diuretics.
Timing Requirement To avoid interference with the antiplatelet effect of low-dose, immediate-release Aspirin, Femen must be administered either at least 8 hours prior to or at least 30 minutes after the aspirin dose.
Substance & Population Alcohol consumption increases the risk of serious gastrointestinal bleeding when combined with Femen. Elderly patients are recognized as being at a greater risk for serious gastrointestinal adverse events during co-administration with interacting substances.

Mechanism of Action

Mechanism of Action: Modulating Prostanoid Pathways

Femen's mechanism involves interference with enzyme activity to produce coordinated physiological adjustments at both central and peripheral sites. The core mechanism involves the non-selective, reversible inhibition of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2.

These enzymes synthesize Prostaglandins, which function as key mediators in local physiological responses. Suppression of Prostaglandin production modifies the chemical environment that propagates inflammatory responses and nociceptor sensitization.

Concurrently, the central mechanism occurs within the hypothalamus, where the active ingredient reduces the synthesis of Prostaglandin E2 ( PGE2 ), the mediator responsible for elevating the body's thermal set-point during disturbances. This action modifies the central control mechanism, resulting in the initiation of physiological heat dissipation processes.

The overall mechanism limits the chemical sensitization of nociceptors (pain-sensing neurons) at peripheral sites. Reduction of inflammatory mediators in the tissue raises the threshold required for pain signals to be transmitted to the central nervous system.

Dosage and Administration Information

Femen is administered primarily via the oral route using tablets or capsules, though a solution for intravenous (IV) infusion is also utilized in controlled clinical settings. The fundamental principle for use is to employ the lowest effective dose for the shortest duration necessary for symptomatic control.

For oral use, the standard adult dose typically begins at 200 mg to 400 mg per administration. Dosing is scheduled on an as-needed basis with a frequency generally noted as every 4 to 6 hours, ensuring a proper time interval between doses. The maximum dose for non-prescription use is typically 1200 mg per day, while prescription-strength regimens can range up to a total of 3200 mg daily in divided doses.

The drug is generally intended for short-term use only, with standard recommendations of a maximum of 10 days for pain and 3 days for fever. Procedural instructions state that oral doses should be taken with a full glass of water and may be administered with food or milk to aid tolerance. For specific populations, such as older adults, it is emphasized that use should be initiated at the lower end of the dosing range. The IV formulation requires dilution prior to administration and must be delivered via infusion over a minimum of 30 minutes.

Recent Clinical Evidence

Research evidence / Overview of Studies for Femen

Research Overview for Primary Dysmenorrhea (Menstrual Pain)

Research for this condition was studied for women of reproductive age experiencing primary dysmenorrhea, which is a condition characterized by fluctuating or episodic manifestations. The primary evidence base comes from Randomized Controlled Trials (RCTs) and Systematic Reviews that synthesize trial data. These studies research examined patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level during periods of heightened symptom activity.

Trials report how symptoms evolved in the observed populations during the study period. Evidence derived from these settings includes short-term measurements, typically during a single menstrual cycle. Research highlights changes measured during the study period related to the frequency of rescue pain medication use and how pain was reported to affect daily activities.

Research Overview for Acute Pain Conditions

Research explored the substance in conditions involving periods of heightened symptoms, such as headaches, dental pain following procedures, and muscular aches/sprains. This body of research primarily consists of short-term RCTs that focused on specific pain models, where research explored outcomes related to physical discomfort. Studies monitored outcomes describing episodic or acute changes and often involved comparisons against non-active substances.

In studies conducted during periods of increased symptom activity, findings describe patterns observed in the studies related to the proportion of patients reporting meaningful changes in symptom intensity. For acute pain scenarios like dental pain, trials report how symptoms evolved in the observed populations over intervals of hours to a few days. The evidence contributes to the broader evidence landscape.

Research Overview for Fever (Antipyresis)

Research for fever was evaluated in settings involving a temporary physiological imbalance characterized by elevated body temperature. Evidence comes from RCTs and comparative trials researching short-term symptom changes in adults and children experiencing acute febrile illness. The studies primarily measured outcomes related to systemic or functional imbalance by monitoring changes in body temperature.

Research data show patterns related to the magnitude and duration of observed changes in body temperature following administration of the tested substance. These findings help contextualize how patients reported their experience by describing how the temperature evolved in the observed populations over defined time intervals. Research provides insight into short-term changes in body temperature.


Research Gaps and Areas of Uncertainty

The research highlights what is known, but evidence also indicates what is still uncertain. The typical follow-up durations were limited, spanning only hours or a few days post-administration. This means that long-term effects are not fully established in the context of continuous or frequent use over extended periods. Data for certain groups remain insufficient, such as older adults with multiple comorbidities, and comparative evidence is lacking in certain specific pain categories.

Frequently Asked Questions (FAQ)

Common questions about Femen (FAQ)


Q: How long does it usually take to notice an effect from Femen?

Studies on the active ingredient indicate that the time to reach maximum concentration in the bloodstream (Tmax) is typically about one to two hours following oral administration of certain formulations. Official product information describes the action as having a relatively rapid onset compared to some other medicines.


Q: Is Femen a drug that is taken daily or only as needed?

Regulatory guidance describes the drug as often used on an "as-needed" basis for temporary relief. Official directions also recommend that use be limited to the shortest duration necessary, often a maximum of 10 days for pain relief.


Q: Can Femen be taken with other pain relievers like ibuprofen?

Femen's active ingredient is a Non-Steroidal Anti-Inflammatory Drug (NSAID). Regulatory documents state that co-administration with other NSAIDs, including other products containing Ibuprofen, is formally listed as a contraindication.


Q: Can Femen be used by people with a history of liver issues?

Official prescribing information states that Femen is strictly contraindicated for use in individuals with severe hepatic failure (very poor liver function). For patients with less severe liver impairment, regulatory documents advise that use requires caution.


Q: Are there different strengths of Femen, and what do they mean?

The active ingredient in Femen is regulated and sold in different strengths. Official information distinguishes between non-prescription (Over-the-Counter or OTC) strengths, which are available without a prescription, and prescription-only strengths. The total permitted daily dosage differs based on the strength classification.


Q: What if I accidentally miss a day of Femen?

Since regulatory instructions describe Femen's use as 'as-needed' rather than a routine daily schedule, there are typically no explicit instructions for a 'missed dose.' The primary constraint noted in official directions is ensuring that the proper time interval is maintained between administrations and that the maximum daily limit is not exceeded.


Q: How long does Femen stay in the body after stopping use?

Pharmacokinetics data, which describes how the body processes the medicine, shows that the active ingredient has a relatively short plasma half-life of around two hours in healthy adults. Official documents indicate that the medicine's elimination from the body is nearly complete within about twelve hours following a standard therapeutic dose.


Q: Does Femen have any known effects on sleep patterns?

Official reports on documented adverse reactions sometimes list Central Nervous System (CNS) effects in the rare or less common categories. These reported effects can include feelings of sleepiness, drowsiness, or, conversely, sleeplessness.


Q: Can Femen be taken with diabetes medications?

Regulatory drug interaction documents list potential interactions with antidiabetic medicines. Regulatory documents indicate that coadministration may potentiate the risk of certain complications, and therefore, use in this situation requires caution as described in official guidance.


Q: Does Femen cause changes in mood or emotions?

Official adverse reaction reports sometimes list psychiatric or Central Nervous System (CNS) effects in the less common categories. These reports have included descriptions of changes such as feelings of anxiety or depression.


Q: Can Femen cause weight changes?

Regulatory documents list 'fluid retention' and 'edema' (swelling, especially in the extremities) as documented side effects. Official warnings sometimes note that unusual weight gain due to this fluid retention can be a sign of a more serious adverse effect.


Q: What does the patient information leaflet say about Femen and driving?

Official product information often includes warnings that certain side effects, such as dizziness, drowsiness, headaches, or vision changes, may occur. Official documents state that if these effects occur, they may impair a person's ability to safely drive or operate machinery.


Q: What does official data say about Femen and fertility?

Regulatory documents state that, based on how the active ingredient works, the use of Femen may temporarily impair female fertility by interfering with the process of ovulation. This effect is described as reversible upon stopping the medicine.


Q: Is Femen suitable for women who have gone through menopause?

Regulatory guidance defines special precautions for the population of older adults (typically over 65), citing an increased risk of certain serious side effects. The official documents do not include specific exclusions or suitability statements based solely on a person's post-menopausal status.


Q: Is Femen safe to use for a long period of time?

Regulatory documents advise that the risk of serious cardiovascular and gastrointestinal adverse events is generally considered to increase with higher doses and longer durations of use. Official non-prescription guidance states that the medicine is limited to a maximum of ten days for pain or three days for fever, unless use is otherwise directed by a healthcare professional.


Q: Do studies show a specific success rate for Femen?

Official research summarizes how the substance works in different conditions, describing that a proportion of patients reported meaningful changes in symptom intensity during the study period. Success rates are typically reported in the context of specific research studies, such as the percentage of patients achieving a defined reduction in pain scores at specific time intervals.


Q: Can I use Femen if I have a sensitive stomach?

Regulatory information lists common stomach-related adverse reactions, such as nausea and dyspepsia. Femen is strictly contraindicated for those with active gastrointestinal bleeding or peptic ulceration. Regulatory guidance indicates that patients with a history of such digestive tract issues are a population that requires caution.


Q: Are there any specific lifestyle changes recommended when using Femen?

Regulatory documents describe that alcohol consumption increases the risk of serious gastrointestinal bleeding. For this reason, official information recommends limiting or avoiding alcohol during use.


Q: How soon after starting Femen should a person check back with their doctor?

Official non-prescription guidance advises that a person should consult a healthcare professional if the medicine is needed for longer than ten days for pain or three days for fever. Consultation is also advised if symptoms worsen or if they do not improve during the period of use.


Q: Is Femen available over-the-counter in any country?

Regulatory frameworks worldwide define the active ingredient in Femen as authorized for use in non-prescription (Over-the-Counter or OTC) forms, as well as prescription-only forms. This distinction depends on the dosage strength being sought.

How should Femen be stored and disposed of?

The storage and disposal of Femen (Ibuprofen tablets/capsules) must follow specific regulatory requirements to ensure stability and safety.

Storage Requirements

Femen must be stored at controlled room temperature, typically between 20^circC and 25^circC (68^circF and 77^circF). It is essential to protect the medicine from moisture and excessive heat; therefore, storage in humid environments like bathrooms is prohibited. The medicine must be kept in its original container, which should be tightly closed when not in use. A crucial safety requirement is to keep Femen out of the sight and reach of children.

Disposal Instructions

Unused or expired Femen should be disposed of according to local regulatory requirements. Official guidance advises against discarding the medicine via wastewater. If a drug take-back program is unavailable, secure disposal involves mixing the medicine with an unpalatable substance before placing it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Femen found in:

A-Z Index: